Hernexeos, zongertinib
Hernexeos (zongertinib) has FDA accelerated approval for adults with advanced non-squamous lung cancer whose tumors have HER2 (ERBB2) activating mutations. Not available where you live? Your doctor may be able to request it by named-patient import. Reserve Meds coordinates the US supply and paperwork and quotes your costs in writing first.
Named-patient access overview. Hernexeos is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Hernexeos
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Hernexeos
Hernexeos (zongertinib) is manufactured by Boehringer Ingelheim and received US FDA accelerated approval in 2025 for adults with previously treated, HER2 (ERBB2)-mutant locally advanced or metastatic non-small cell lung cancer. It is an oral, irreversible HER2-selective tyrosine kinase inhibitor, designed to target HER2-mutant tumor signalling while sparing wild-type EGFR, which is the basis for the safety and efficacy profile observed in the Beamion LUNG-1 pivotal trial.
Hernexeos is taken by mouth once daily as set out in the prescribing information, with dose adjustments for diarrhea, transaminase elevation, interstitial lung disease, and other label-listed adverse events. HER2 mutation status on tissue or plasma must be confirmed before treatment. For international patients, Hernexeos may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the patient's treating oncologist handling the documentation.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Hernexeos
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Hernexeos for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Hernexeos is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list zongertinib as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Hernexeos in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Hernexeos
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Hernexeos if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Hernexeos for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Hernexeos through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Hernexeos. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Hernexeos through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Hernexeos to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Hernexeos to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Hernexeos cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Hernexeos?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.